Form 4: Merck & Co. Director Mary Ellen Coe Reports Acquisition of Phantom Stock Units

Mary Ellen Coe, a director of Merck & Co., Inc., reported the acquisition of phantom stock units settled in cash, according to a recent SEC Form 4 filing.

Summary

• On May 31, 2024, Mary Ellen Coe, a director of Merck & Co., acquired phantom stock units that will be settled in cash upon termination of service.
• The transaction involved 1,752.4295 phantom stock units at a price of $125.54, resulting in a holding of 22,927.3613 derivative securities.
• The phantom stock units are to be settled 100% in cash upon the reporting person's termination of service, according to a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
• Holdings include shares acquired in dividend reinvestment transactions.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating a neutral to slightly positive sentiment as it aligns director interests with company performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• Dividend reinvestment transactions increase the director's stake in the company.

Future Outlook

The phantom stock units will be settled in cash upon the reporting person's termination of service, according to a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

Industry Context

This filing is a routine disclosure of a director's acquisition of phantom stock units, which is a common form of executive compensation in publicly traded companies. It reflects the director's investment in the company's future performance.

Comparison to Industry Standards

• Phantom stock grants are a common compensation tool used by companies like Merck & Co. to align director and executive incentives with shareholder value.
• Companies such as Pfizer and Johnson & Johnson also utilize similar equity-based compensation plans for their directors and executives.
• The specific terms of the phantom stock plan, such as the vesting schedule and settlement method, are typical for director compensation packages in the pharmaceutical industry.

Stakeholder Impact

• The acquisition of phantom stock units aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates